13.57
price up icon10.24%   1.26
pre-market  Vorhandelsmarkt:  15.39   1.82   +13.41%
loading
Schlusskurs vom Vortag:
$12.31
Offen:
$13.5
24-Stunden-Volumen:
2.51M
Relative Volume:
3.71
Marktkapitalisierung:
$740.88M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-5.7257
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
+15.49%
1M Leistung:
+17.18%
6M Leistung:
+35.43%
1J Leistung:
-10.43%
1-Tages-Spanne:
Value
$13.31
$14.78
1-Wochen-Bereich:
Value
$11.69
$14.78
52-Wochen-Spanne:
Value
$5.35
$16.15

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
Firmenname
Stoke Therapeutics Inc
Name
Telefon
781-430-8200
Name
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Name
Mitarbeiter
128
Name
Twitter
@stoketx
Name
Nächster Verdiensttermin
2025-03-18
Name
Neueste SEC-Einreichungen
Name
STOK's Discussions on Twitter

Vergleichen Sie STOK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
STOK
Stoke Therapeutics Inc
13.57 641.51M 8.78M -104.70M -82.68M -2.37
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-18 Eingeleitet Jefferies Buy
2024-12-20 Eingeleitet Chardan Capital Markets Buy
2024-10-14 Fortgesetzt Leerink Partners Outperform
2024-03-26 Hochstufung TD Cowen Market Perform → Outperform
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-07-25 Herabstufung TD Cowen Outperform → Market Perform
2023-05-01 Hochstufung BofA Securities Underperform → Neutral
2023-04-26 Fortgesetzt Canaccord Genuity Buy
2023-01-06 Herabstufung BofA Securities Buy → Underperform
2022-10-24 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-01-31 Eingeleitet Jefferies Buy
2021-12-03 Eingeleitet BofA Securities Buy
2021-11-22 Hochstufung JP Morgan Neutral → Overweight
2021-05-18 Eingeleitet UBS Neutral
2021-05-10 Hochstufung Wedbush Neutral → Outperform
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-02-10 Herabstufung Wedbush Outperform → Neutral
2020-12-15 Fortgesetzt H.C. Wainwright Buy
2020-12-11 Bestätigt Needham Buy
2020-10-23 Eingeleitet Cantor Fitzgerald Overweight
2020-09-29 Fortgesetzt JP Morgan Neutral
2020-09-29 Eingeleitet Needham Buy
2019-12-18 Eingeleitet Wedbush Outperform
2019-11-12 Eingeleitet BTIG Research Buy
2019-10-25 Eingeleitet H.C. Wainwright Buy
2019-07-15 Eingeleitet Canaccord Genuity Buy
2019-07-15 Eingeleitet Cowen Outperform
2019-07-15 Eingeleitet Credit Suisse Outperform
2019-07-15 Eingeleitet JP Morgan Overweight
Alle ansehen

Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about Stoke Therapeutics Inc. stockRapid growth opportunities - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Stoke Therapeutics Inc. stock attracts strong analyst attentionProven Return Strategy Execution - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-22 13:02:52 - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Stoke Therapeutics Inc. Stock Analysis and ForecastUnprecedented profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What drives Stoke Therapeutics Inc. stock priceRecord-setting profit potential - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Is Stoke Therapeutics Inc. a good long term investmentExceptional profit velocity - PrintWeekIndia

Jul 21, 2025
pulisher
Jul 20, 2025

Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 19, 2025

Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛

Jul 19, 2025
pulisher
Jul 19, 2025

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st

Jul 19, 2025
pulisher
Jul 19, 2025

Stoke Therapeutics (STOK): A High-Conviction Buy with Disease-Modifying Potential in Dravet Syndrome - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating - GuruFocus

Jul 18, 2025
pulisher
Jul 18, 2025

Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 11:35:29 - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 17, 2025

Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 16, 2025 - BioSpace

Jul 17, 2025
pulisher
Jul 16, 2025

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

How Stoke Therapeutics Inc. stock performs during market volatilityProven Trading Plan - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Stoke Therapeutics Inc. stock price move sharplyDaily Price Surge List - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago - Yahoo Finance

Jul 15, 2025
pulisher
Jul 12, 2025

Canaccord Genuity Keeps Their Buy Rating on Stoke Therapeutics (STOK) - The Globe and Mail

Jul 12, 2025
pulisher
Jul 11, 2025

Case builds for Biogen, Stoke's Dravet syndrome drug - pharmaphorum

Jul 11, 2025
pulisher
Jul 10, 2025

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Ariva

Jul 10, 2025
pulisher
Jul 10, 2025

Biogen (BIIB) Presents Promising Data from Zorevunersen Studies - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Revolutionary Dravet Syndrome Treatment: Biogen's Zorevunersen Delivers Cognitive Gains in Phase 3 Trial - Stock Titan

Jul 10, 2025

Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):